uniQure (NASDAQ:QURE) Shares Gap Up – Time to Buy?

uniQure (NASDAQ:QURE) gapped up before the market opened on Tuesday . The stock had previously closed at $17.43, but opened at $17.88. uniQure shares last traded at $16.88, with a volume of 148,236 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on QURE shares. Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research report on Tuesday, December 10th. StockNews.com raised uniQure to a “sell” rating in a research report on Wednesday, December 11th. Royal Bank of Canada raised their price target on uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Finally, Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Stock Down 0.5 %

The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business’s 50-day simple moving average is $8.60 and its 200-day simple moving average is $6.95. The company has a market capitalization of $845.69 million, a PE ratio of -3.50 and a beta of 0.89.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities research analysts anticipate that uniQure will post -3.82 EPS for the current fiscal year.

Insider Buying and Selling at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

Hedge funds have recently added to or reduced their stakes in the company. RTW Investments LP purchased a new stake in shares of uniQure during the 3rd quarter worth about $49,000. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc purchased a new position in uniQure during the third quarter worth approximately $53,000. Quarry LP acquired a new stake in uniQure in the third quarter valued at approximately $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,306 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.